Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 8, 2026

Back to the front page

Post Q3 EVC Update

EVC's Q3 update cites $30 million for a single station, a broadcast-business sale and stronger positioning for 2027.

EVC $832M
Nat Stewart - Stock Picking Newsletter 23 clicks

From X

@aleabitoreddit

Serenity on X

It think it's stupid that "AI Bubble" gets used over and over. In infra names you have: - 1-3x fwd P/E memory companies from Samsung to $ESMT. With HBM players now having hyperscaler multi-year price floor LTAs. - Optical companies like $POET traded -$97M under net cash. Valuing the operating business very negatively, not even at $0. - While AI companies with larger premiums continue to record demand over the next 3-5 years. Such as the new $20B LTAs signed w/ $COHR to $5B LTAs signed w/ $LITE. Can someone in the media honestly see negative EV high-beta optical companies, where 2 years of burnrate would still value the company below $0. or single digit memory companies with contracted demand + price floors years out and say that's a bubble? Many of these names are extremely profitable today... But obviously there's other elements inside the theme, such as: - Certain startups like Instinct that look like a private valuation bubble. - Leveraged Neoclouds that didn't finance properly - and AI lab valuations and commitments, which should be viewed cautiously. But everything gets grouped into one with the boogyman of "leverage" or "debt". Yes, valuations can compress or correct from macro, potential regulatory uncertainty, or potential capex reductions. But for the companies physically powering the AI buildout, it looks more like the Great AI Deleveraging of 2026... Than anything like fundamental demand destruction. As more earnings come out and free cash flow accumulates over time. I'm confident in a recovery, especially in bottlenecks, and for markets to eventually discern durability + growth over frothy valuations tied to AI.
@calvinblissett

Calvin Blissett on X

$PDEX: Pro-Dex (PDEX) makes powered surgical handpieces (drivers and shavers) used mainly in orthopedic, thoracic (chest), and CMF (face/skull) surgeries. They design, build, and repair them primarily for medical device OEMs (one big customer drives most sales), plus some precision machining for aerospace/defense after a 2026 acquisition.⁠ New/upcoming products: Ongoing next-generation orthopedic handpiece for their largest customer (contract through 2028). Helios Pro: latest off-the-shelf CMF/cranial driver with their adaptive torque-limiting software (released for production). Articulating attachment (in development; targeting production spring/summer 2027). Monogram validation units (with Monogram Technologies/Zimmer Biomet; expected later in FY2027). Other roadmap items include a spinal driver and smart driver. Quick Pitch Market Cap $202m=Enterprise Value. Warren Buffett's Owner's Earnings of $13.45m resulting in a 15x multiple. W/C consistently a drag on cashflow. Feb 2026 acquired APM getting them into aerospace and defense. Repair revenue (probably high margin reoccurring) declining as largest customer shifts away from legacy devices. CEO been with co since 2006 and CEO since 2015. CFO been CFO since 2015
@calvinblissett 1 click

Calvin Blissett on X

$EMBC: Embecta (EMBC), spun out of Becton Dickinson in 2022, makes the pen needles and syringes people with diabetes use to inject insulin. Its U.S. pen needle business is shrinking from lost share and price cuts, and more patients are moving from daily insulin shots to weekly GLP-1s. To offset that, it is selling its needles inside the boxes of generic GLP-1 drugs, already launched in India, Canada and Brazil and targeted at $100M+ in revenue by 2033. It is also launching cheaper needles and syringes for new markets and buying into other drug-delivery products beyond insulin. Quick Pitch $350m Market Cap/$1.62B Enterprise Value. Less than 3x P/E. Warren Buffett Owners Earnings of $122m ex SBC. Cut dividend switched to $100m Buyback authorization that's being used. CEO/CFO/Director/CLO all bought August 12th
@calvinblissett

Calvin Blissett on X

$AIRT: Air T is a holding company for aviation businesses. Its companies fly cargo and regional feeder routes, sell and repair aircraft parts, and provide airport equipment, software, and aircraft leasing. Air T owns cargo/feeder flying, aircraft parts and repair, airport equipment/software, and leasing businesses. At $27.70, market cap is about $75m. Enterprise value is about $304m including debt, or ~$351m including leases, earnouts, and minority claims. FY25 cash flow less all capex was $7.8m: a tempting 9.6x market-cap multiple. But working capital contributed ~$22m of cash that year; adjusting for it makes that owners’ earnings proxy negative ~$14.6m. FY26 cash flow less capex was -$41.5m. FY26 net income included a $111m noncash bargain-purchase gain—not operating earnings. No open-market common-stock insider buys found; a July Form 144 tied to CEO Nick Swenson proposed selling 10k preferred securities, which doesn’t confirm a completed sale. Rex could drive growth, but integration, debt, inventory, thin margins, and fuel costs are risks. Air cargo demand is growing: IATA reported +4.4% in August.
@MaiusPartners 1 click

Maius on X

$PSIX Q3 results and recent power sector thoughts: The company delivered an exceptional Q3 clean “beat and raise” by any measure — even better than the record Q2 2025, when the stock peaked at over $100, with a much better story today. Yet the stock trades at a fraction of the valuation, Why? Long-term followers know we turned constructive on $PSIX only recently after an extensive amount of fundamental work and have not been afraid to be critical in the past. It was a meaningful position heading into the print. Given broader sector risks, we also held several related short positions as a factor hedge. However, after analysing $ANT S1 filings and election results, we think the narrative has shifted materially over the past week and when the facts change, it’s always important to reassess one’s central beliefs and have opted to close the majority of the long positions in $PSIX (retaining an OTM call option), while keeping all the shorts. The high level math: ~30 GW of behind-the-meter power capacity is scheduled to become available in 2027, scaling to >100 GW by 2030 if the dozen suppliers deliver on announced expansions (many won’t). Absent major changes in U.S. politics or AI model diffusion rates to support far higher collective monetisation rates across the entire industry, rapid buildout of new data centres on American soil can neither be justified economically, nor politically, a view held by the credit markets for some time, but only just beginning to be priced in by equity investors. The behind the meter power industry risks moving quickly into excess in such a scenario, with incremental suppliers at especially high risk. $PSIX has been one of the top-performing behind-the-meter power plays we track since our recent full note. Its unfortunate market conditions changed so quickly, substantially reducing the probability of developing into the multi-bagger we envisioned. Congrats to everyone who made money in this sector the past few months, it certainly hasn’t been easy (especially on the long side!) — and have a great weekend! DMs always open for those wanting to discuss further.

Investor Letters

All letters

GREAT DEC-TECTIVE WORK

Diversified Energy reported $255.6 million of “true” nine-month free cash flow, while its $1.8 billion Birch acquisition would shift…

DEC $900M
The Oak Bloke 2 clicks

Research Note

Nine Mile Metals is the subject of a research note.

VMSXF $14M
Atrium Research - Equity Research 4 clicks

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

SITC $192M
Real Assets, Real Value 5 clicks

Namib Minerals: Research Flash

Namib Minerals accelerates Redwing’s restart, targeting first gold this month and a ramp from 338 ounces monthly to 835 ounces by Q2 2027.

NAMM $46M
Atrium Research - Equity Research 7 clicks
BNTC · long

Benitec Biopharma INC

Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.

BNTC $293M
Value Investors Club

Forgive me Father, I have Sabled.

Sable Offshore restarted Santa Ynez oil flows under a Defense Production Act order, targeting 50,000 barrels daily and a path to 60,000…

SOC $349M
Triple S Special Situations Investing 3 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 279

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.